Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

There are currently no effective treatments for Ebola, but blood plasma from people who have survived Ebola may be one potential treatment: this component of blood may contain antibodies that likely helped survivors successfully fight off the disease.

Health care worker wearing PPE

There are currently no effective treatments for Ebola, but blood plasma from people who have survived Ebola may be one potential treatment: this component of blood may contain antibodies that likely helped survivors successfully fight off the disease.

During the 2015 Ebola outbreak in West Africa researchers carried out the largest ever trial of convalescent plasma for the treatment of Ebola.  They found that such treatment during an Ebola virus disease outbreak is feasible and safe to use, and acceptable to donors, patients and health workers.

The study was conducted at the Donka Ebola Treatment Centre in Guinea, run by Médecins Sans Frontières (MSF), and carried out by a consortium led by Professor Johan van Griensven from the Institute of Tropical Medicine in Antwerp that includes Professor Peter Horby from the Epidemic diseases Research Group (ERGO) at the University of Oxford.

The full story is available on the University of Oxford website

Similar stories

Global Research on AntiMicrobial resistance (GRAM) project

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.

Susie, Phaik Yeong, Richard and Paul among new full Oxford professors!

In the 2021 Oxford Recognition of Distinction round, four MORU colleagues were awarded Full Professor title.

RECOVERY Trial launches in South Africa

The world’s largest clinical trial investigating treatments for COVID-19 has now launched in South Africa, with the first patient recruited today. This is the fifth country to take part in RECOVERY, joining Nepal, Indonesia, Vietnam, and the United Kingdom.

RECOVERY Trial wins ‘Oscar of Higher Education’ for STEM Research Project of the year

The RECOVERY Trial has been awarded the 2021 Times Higher Education (THE) Award in the ‘Research Project of the Year: STEM’ category.

Antibiotic accountability: how countries and companies perform

Patients in north Africa and the Middle East are using antibiotics in sharply rising quantities far beyond the global average, raising concerns over the escalating risks of resistance to medicines to treat bacterial infections. Estimated antibiotic consumption for 204 countries between 2000 and 2018 shows a 46 per cent increase in global antibiotic usage, with a surge in nations including India and Vietnam.

Paul Newton named ASTMH Distinguished International Fellow

Professor Paul Newton was announced new Distinguished International Fellow at the ASTMH Annual Meeting Awards Ceremony on the 17th November. This distinction formally recognizes individuals who have made eminent contributions to a particular aspect of tropical medicine or hygiene.